Interactive Session:
202. Clinical Controversies
Saturday, October 10, 2015: 10:30 AM-12:00 PM
Room: 20--ABCD
Co-organized with the IDSA Clinical Affairs Committee

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the evidence for and against long-sleeve shirts and white coasts as transmission vehicles for MDRO
  • discuss the pros and cons of using fecal microbiota transplantation as first line therapy for C. difficile infection
  • summarize the reasoning behind moving atazanavir and efavirenz to second line status for treatment of HIV infection

Target Audience: Nurses, Members-in-training, Infectious diseases physicians, Infectious diseases pediatricians, Infection preventionists, Hospital epidemiologists, Hospital administrators, HIV specialists, HIV clinicians, Healthcare workers, Fellows, Epidemiologists, Clinicians

Tracks: Trainee, Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Interactive Moderators:  Patrick Joseph, MD, FIDSA, University of California, San Francisco and J Trees Ritter, DO, FIDSA, Central Coast Infectious Diseases Consultants

Interactive Panelists:  Michael Edmond, MD, MPH, MPA, FIDSA, FSHEA, University of Iowa Carver College of Medicine , Neil O. Fishman, MD, FSHEA, University of Pennsylvania Perelman School of Medicine , Thomas Moore, MD, FIDSA, University of Kansas School of Medicine-Wichita Campus , Johan S Bakken, MD, PhD, FIDSA, St. Luke ID Associates , Roy M. Gulick, MD, MPH, FIDSA, Weill Cornell Medical College and Joseph Eron, MD, University of North Carolina at Chapel Hill

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-15-199-L01-P

Disclosures:

P. Joseph, None

J. T. Ritter, None

M. Edmond, None

N. O. Fishman, None

T. Moore, None

J. S. Bakken, Rebiotix Inc.: Scientific Advisor , No financial support since 2012

R. M. Gulick, None

J. Eron, Merck: Consultant , Consulting fee and Speaker honorarium
GSK: Consultant and Grant Investigator , Consulting fee , Grant recipient and Speaker honorarium
ViiV: Consultant and Grant Investigator , Consulting fee , Grant recipient and Speaker honorarium

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.